Search clinical trials for: Placebo of Aliskiren

Total 182598 results

Medical University of Gdansk

Completed

Influence of Aliskiren on Albuminuria After Kidney Transplantation

Albuminuria

Poland
Novartis Pharmaceuticals

Completed

An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

Hypertension

United States, Hungary, Turkey, Guatemala, Slovakia, Puerto Rico, Poland
Novartis

Completed

Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg

Hypertension

China, India, Thailand
Brigham and Women's Hospital

Terminated

Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance

Insulin Sensitivity | Diastolic Function | Aortic Compliance

United States
Novartis

Completed

Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.

Healthy

United States
Novartis

Completed

Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension (AIMS)

Hypertension

United States
Region Skane

Recruiting

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Membranoproliferative Glomerulonephritis | Complement Abnormality

Sweden
Novartis

Completed

Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.

Healthy

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure (ATMOSPHERE)

Chronic Heart Failure

China, United States, Belgium, Colombia, India, Korea, Republic of, Poland, Romania, Italy, Spain, Austria, Estonia, France, Germany, Japan, Taiwan, Turkey, Netherlands, Sweden, Switzerland, United Kingdom, Thailand, Australia, Ireland, Russian Federation and more
Novartis

Completed

8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension (VANTAGE)

Stage 2 Hypertension

United States
Centre Hospitalier Universitaire Vaudois

Completed

Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension

Hypertension

Switzerland
Assaf-Harofeh Medical Center

Unknown

Aliskiren's Effect on Arterial Stiffness and Platelet Function in Patients With Diabetes Mellitus (DM)

Diabetes Mellitus | Atherosclerosis
Columbia University
Novartis Pharmaceuticals

Terminated

Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease

Diabetic Nephropathy | Focal Segmental Glomerulosclerosis | IgA Nephropathy | Glomerulonephritis, Membranous | Hypertensive Nephrosclerosis | Proteinuric Kidney Disease | Glomerulopathy (Obesity-associated)

United States
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

A New Surgical Strategy to Protect the Inferior Parathyroid

Thyroid Cancer

China
University of Michigan
Novartis Pharmaceuticals

Withdrawn

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome (SAAVE)

Hypertension | Metabolic Syndrome

United States
Novartis

Completed

Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population (ACTION)

Hypertension

United States
HeartDrug Research LLC
Novartis

Unknown

Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics

Diabetes Mellitus

United States
Medical University of Vienna

Completed

RAS Quantification in Patients With Aliskiren or Candesartan (RASQAL)

Hypertension | Proteinuria | Chronic Kidney Disease

Austria
Vanderbilt University Medical Center

Completed

Aldosterone and the Metabolic Syndrome

Glucose Metabolism Disorders | Metabolic Diseases | Diabetes Mellitus | Endocrine System Diseases

United States
Novartis

Completed

Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension (ACADEMY)

Stage II Hypertension

Thailand
The University of Hong Kong

Completed

Aliskiren Combined With Losartan in Proteinuric, Non-diabetic Chronic Kidney Disease

Kidney Disease

China
Medical University of Gdansk

Completed

The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria

Proteinuria | Chronic Kidney Disease
Swiss Federal Institute of Sport Magglingen

Unknown

Comparison of the Automatized and the Optimized Carbon Monoxid Rebreathing Protocol

Hemoglobins

Switzerland
Medical University of Gdansk

Completed

Influence of Aliskiren on Proteinuria (ALIPRES)

Proteinuria | Chronic Kidney Disease | Blood Pressure

Poland
Novartis

Completed

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

Hypertension

Sweden, United States, Romania, Denmark, Israel, Italy, Germany, Australia, Canada, Latvia, Lithuania, Turkey
Nagoya University

Unknown

Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy (EARTH)

Hypertensive Left Ventricular Hypertrophy

Japan
Novartis

Completed

Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension (AMAZING)

Hypertension

Germany
University of Pavia

Unknown

Effects of Aliskiren/Amlodipine Versus Amlodipine Monotherapy on Ankle-foot Volume in Hypertensive Patients

Hypertension

Italy
Novartis

Completed

Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension (AACESS)

Hypertension

United States
Texas Tech University Health Sciences Center

Completed

Direct Renin Inhibition Effects on Atherosclerotic Biomarkers

Coronary Artery Disease | Type 2 Diabetes Mellitus

United States
William Beaumont Hospitals
Novartis Pharmaceuticals

Withdrawn

Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics

Hypertension | Diabetes Type 2

United States
Novartis

Completed

A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.

Hypertension

United States, Canada, Germany, Netherlands
Hospital Universitario Pedro Ernesto
Novartis

Withdrawn

Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan

Hypertension | Diabetes Mellitus

Brazil
University of Campania "Luigi Vanvitelli"
IRCCS San Raffaele

Unknown

Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients

Hypertension | Dialysis

Italy
Novartis

Completed

Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension (ATTAIN)

Hypertension

United States
Novartis

Completed

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Samsung Medical Center

Completed

Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS

Marfan Syndrome

Korea, Republic of
Amsterdam UMC, location VUmc
Novartis

Terminated

Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension (PISA)

Hypertension | Abdominal Aortic Aneurysm

Netherlands
Novartis

Completed

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone

Hypertension

Sweden, Slovakia, Argentina, Germany, Turkey, Norway, Poland
Novartis

Completed

Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension

Essential Hypertension ( Mild to Moderate)

Romania, Slovakia, Hungary, France
Novartis

Completed

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

Essential Hypertension

Spain, United States, Belgium, Egypt, Germany, Poland, Slovakia, Turkey
Novartis

Completed

Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension

Moderate to Severe Hypertension

Russian Federation, Romania, Singapore, Spain, Germany, Philippines
Novartis

Completed

An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

Hypertension

United States, Belgium, Denmark, Finland, Germany, Iceland, India, Switzerland
Novartis Pharmaceuticals

Completed

Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients

Hypertension

Russian Federation
Novartis

Completed

Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus (ASTRIDE)

Hypertension | Diabetes Mellitus

United States
The Rogosin Institute

Terminated

Combined Renin Inhibition/Beta-blockade

Hypertension

United States
Ege University

Completed

Care to Caregiver: The Effect of Reflexology on Sleep and Anxiety of Cancer Caregiver

Sleep | Anxiety

Turkey
Novartis

Terminated

Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome (ALTO)

Hypertension With Metabolic Syndrome

United Kingdom
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder (DEPIL-2)

Bipolar Depression

France
Washington University School of Medicine

Completed

Alirocumab and Reverse Cholesterol Transport

Atherosclerosis | Coronary Heart Disease

United States

3

Subscribe